Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial
The two companies have selected one of the four candidates they were developing and testing in early-stage trials.
Full Article
Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial
Motley Fool
0 shares
1 views
You might like
Related news coverage
Is Coronavirus Vaccine Made From Fetal Cell Lines?
Eurasia Review
By Matt Hadro
As coronavirus vaccine prototypes move closer to testing and approval, some Catholics are debating the..
-
Is the coronavirus vaccine made from fetal cell lines?
CNA
-
Pandemic hurts sales, profit for Pfizer amid restructuring
SeattlePI.com
-
Coronavirus: German/US vaccine candidate cleared for Phase 2 and 3 clinical trials
Deutsche Welle
-
Coronavirus: Pfizer and BioNTech announce global vaccine trial
Independent
Advertisement
More coverage
MRNA, PFE/BNTX COVID-19 Vaccines Move Into Phase 3, CytoDyn On Watch, GNCA To Report Data On Jul.30
RTTNews
Today's Daily Dose brings you news about Moderna moving its COVID-19 vaccine candidate into phase III testing, Pfizer/BioNTech..
-
Coronavirus | Pfizer-BioNTech begin global study of lead vaccine candidate
Hindu
-
FTSE 100 clinging on to gains as sterling rallies
Proactive Investors
-
FTSE 100 shrugs off latest episode in US-China muscle-flexing contest
Proactive Investors
-
FTSE 100 to start Thursday a sliver as traders balance vaccine hopes and US-vs-China fears
Proactive Investors